Thank you for taking our quiz on PsA from results presented at ACR Convergence 2020! How did you do?
1) DMARD-naïve patients achieving Routine Assessment of Patient Index Data 3 (RAPID3) and the Clinical Disease Activity for Psoriatic Arthritis (cDAPSA) targets with apremilast (Otezla), showing early and sustained improvements after how long?
a) 52 weeks
b) 32 weeks
c) 24 weeks
d) 16 weeks
The Answer is A. In the RAPID3 and cDAPSA analyses, improvements in swollen joints count and TJC were observed for patients with REM or low severity (RAPID3) or REM or LDA (cDAPSA) at week 52. In the RAPID3 analysis, mean TJC was higher than expected at week 52 in patients achieving low severity.
2) In a study presented at ACR 2020, family history of psoriasis (odds ratio [OR] = 2.71, 95% confidence interval [CI] 1.24 – 5.90) and psoriasis severity (OR=1.96, 95% CI 1.26 -3.06) were more likely in those who had a delay in transition from psoriasis to PsA than those who had a concomitant diagnosis.
a) True
b) False
3) 1) Data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2 showed that guselkumab (Tremfya) improved what in adult patients with active psoriatic arthritis (PsA) and maintained response through 52 weeks of active treatment?
a) Swollen joints
b) Bone density
c) Fatigue
d) Disease activity
The Answer is D. As measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale. Guselkumab improved fatigue during the placebo-controlled periods of both studies at week 24, and through one year of active treatment.
4) What drug is the first and only FDA-approved selective anti-IL-23 therapy for active psoriatic arthritis and the only therapy for psoriatic arthritis to have improvement in fatigue as measured by FACIT-F in the product label?
a) Ixekizumab
b) Deucravacitinib (Talz)
c) Guselkumab (Tremfya)
d) None of the above
